Susquehanna International Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.25M Buy
178,391
+79,880
+81% +$2.22M ﹤0.01% 4544
2025
Q4
$2.73M Sell
98,511
-26,635
-21% -$680K ﹤0.01% 5050
2025
Q3
$3.04M Sell
125,146
-462,831
-79% -$9.21M ﹤0.01% 4953
2025
Q2
$10M Buy
587,977
+395,556
+206% +$6.89M ﹤0.01% 2825
2025
Q1
$3.76M Buy
192,421
+61,985
+48% +$1.62M ﹤0.01% 4203
2024
Q4
$3.23M Buy
130,436
+44,789
+52% +$1.14M ﹤0.01% 4339
2024
Q3
$2.1M Sell
85,647
-80,116
-48% -$2.07M ﹤0.01% 5177
2024
Q2
$3.88M Buy
165,763
+84,134
+103% +$2.07M ﹤0.01% 3858
2024
Q1
$2.7M Sell
81,629
-99,110
-55% -$3.09M ﹤0.01% 4713
2023
Q4
$4.92M Sell
180,739
-191
-0.1% -$4.74K ﹤0.01% 3725
2023
Q3
$4.35M Buy
180,930
+156,825
+651% +$4.2M ﹤0.01% 3777
2023
Q2
$770K Sell
24,105
-157,252
-87% -$5.1M ﹤0.01% 7296
2023
Q1
$5.55M Buy
181,357
+127,212
+235% +$5.02M ﹤0.01% 3302
2022
Q4
$2.12M Sell
54,145
-14,945
-22% -$669K ﹤0.01% 4589
2022
Q3
$3.29M Buy
69,090
+5,288
+8% +$302K ﹤0.01% 3892
2022
Q2
$2.47M Sell
63,802
-8,866
-12% -$352K ﹤0.01% 4455
2022
Q1
$4.16M Sell
72,668
-22,588
-24% -$1.48M ﹤0.01% 3970
2021
Q4
$7.59M Buy
95,256
+31,770
+50% +$2.72M ﹤0.01% 3087
2021
Q3
$5.52M Buy
63,486
+44,868
+241% +$4.51M ﹤0.01% 3770
2021
Q2
$2.4M Sell
18,618
-8,039
-30% -$641K ﹤0.01% 5503
2021
Q1
$2.13M Sell
26,657
-41,547
-61% -$3.95M ﹤0.01% 5775
2020
Q4
$5.57M Buy
+68,204
New +$3.35M ﹤0.01% 3250

Other funds holding BEAM

Susquehanna International Group's BEAM Position: Q1 2026 in Review

Susquehanna International Group increased its Beam Therapeutics (BEAM) stake by 81% in Q1 2026, buying an estimated $2.22M and bringing the position to 178,391 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4544.

Susquehanna International Group first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $10M in Q2 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Susquehanna International Group held 178,391 shares of Beam Therapeutics worth $4.25M as of Q1 2026.
  • Susquehanna International Group bought 79,880 Beam Therapeutics shares in Q1 2026, an estimated $2.22M.
  • Beam Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4544 holding.
  • Susquehanna International Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Susquehanna International Group's Beam Therapeutics position peaked at $10M in Q2 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.